Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ · Manufacturing · Pharmaceutical preparations
CVKD price, last 12 months
Key stats
- Previous close
- $1.20
- Open
- $1.25
- Day range
- $1.13 – $1.25
- 52-week range
- $1.00 – $14.64
- Volume
- 224.9K
- Avg volume (20 days)
- 1.2M
- Market cap
- $4.1M
Performance
Technicals and fundamentals
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $4.1M